Characterization of a chemical affinity probe targeting Akt kinases

Journal of Proteome Research

Volumn 12, Issue 8, 2013, Pages 3792-3800

  Pachl, Fiona ^a   Plattner, Patrik ^b   Ruprecht, Benjamin ^a   Médard, Guillaume ^a   Sewald, Norbert ^b   Kuster, Bernhard ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b BIELEFELD UNIVERSITY   (Germany)

^c Munich Center for Integrated Protein Science   (Germany)

Author keywords

Akt; chemical proteomics; kinobeads; mass spectrometry

Indexed keywords

4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; AGC KINASE; CDC42BPB PROTEIN; GSK 2141795; PRKG1 PROTEIN; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR PROBE; PRIORITY JOURNAL; PROTEIN TARGETING; PROTEOMICS;

EID: 84881159771     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr400455j     Document Type: Article

References (55)

1. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome Science 2002, 298 (5600) 1912-1934
2. Cohen, P. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discovery 2002, 1 (4) 309-315
3. Fedorov, O.; Muller, S.; Knapp, S. The (un)targeted cancer kinome Nat. Chem. Biol. 2010, 6 (3) 166-169
4. Page, T. H.; Smolinska, M.; Gillespie, J.; Urbaniak, A. M.; Foxwell, B. M. Tyrosine kinases and inflammatory signalling Curr. Mol. Med. 2009, 9 (1) 69-85
5. Knapp, S.; Arruda, P.; Blagg, J.; Burley, S.; Drewry, D. H.; Edwards, A.; Fabbro, D.; Gillespie, P.; Gray, N. S.; Kuster, B.; Lackey, K. E.; Mazzafera, P.; Tomkinson, N. C. O.; Willson, T. M.; Workman, P.; Zuercher, W. J. A public-private partnership to unlock the untargeted kinome Nat. Chem. Biol. 2013, 9 (1) 3-6
6. Cohen, P.; Alessi, D. R. Kinase drug discovery - what's next in the field? ACS Chem. Biol. 2013, 8 (1) 96-104
7. Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P. Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29 (11) 1046-1051
8. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26 (1) 127-132
9. Anastassiadis, T.; Deacon, S. W.; Devarajan, K.; Ma, H.; Peterson, J. R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29 (11) 1039-1045
10. Nolen, B.; Taylor, S.; Ghosh, G. Regulation of protein kinases; controlling activity through activation segment conformation Mol. Cell 2004, 15 (5) 661-675
11. Shi, Z.; Resing, K. A.; Ahn, N. G. Networks for the allosteric control of protein kinases Curr. Opin. Struct. Biol. 2006, 16 (6) 686-692
12. Bantscheff, M.; Eberhard, D.; Abraham, Y.; Bastuck, S.; Boesche, M.; Hobson, S.; Mathieson, T.; Perrin, J.; Raida, M.; Rau, C.; Reader, V.; Sweetman, G.; Bauer, A.; Bouwmeester, T.; Hopf, C.; Kruse, U.; Neubauer, G.; Ramsden, N.; Rick, J.; Kuster, B.; Drewes, G. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat. Biotechnol. 2007, 25 (9) 1035-1044
13. Brehmer, D.; Greff, Z.; Godl, K.; Blencke, S.; Kurtenbach, A.; Weber, M.; Muller, S.; Klebl, B.; Cotten, M.; Keri, G.; Wissing, J.; Daub, H. Cellular targets of gefitinib Cancer Res. 2005, 65 (2) 379-382
14. Godl, K.; Gruss, O. J.; Eickhoff, J.; Wissing, J.; Blencke, S.; Weber, M.; Degen, H.; Brehmer, D.; Orfi, L.; Horvath, Z.; Keri, G.; Muller, S.; Cotten, M.; Ullrich, A.; Daub, H. Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling Cancer Res. 2005, 65 (15) 6919-6926
15. Wissing, J.; Jansch, L.; Nimtz, M.; Dieterich, G.; Hornberger, R.; Keri, G.; Wehland, J.; Daub, H. Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry Mol. Cell. Proteomics 2007, 6 (3) 537-547
16. Sharma, K.; Weber, C.; Bairlein, M.; Greff, Z.; Keri, G.; Cox, J.; Olsen, J. V.; Daub, H. Proteomics strategy for quantitative protein interaction profiling in cell extracts Nat. Methods 2009, 6 (10) 741-744
17. Wu, Z.; Doondeea, J. B.; Gholami, A. M.; Janning, M. C.; Lemeer, S.; Kramer, K.; Eccles, S. A.; Gollin, S. M.; Grenman, R.; Walch, A.; Feller, S. M.; Kuster, B. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer Mol. Cell. Proteomics 2011, 10 (12 M111 011635
18. Kruse, U.; Bantscheff, M.; Drewes, G.; Hopf, C. Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalized health care Mol. Cell. Proteomics 2008, 7 (10) 1887-1901
19. Rix, U.; Hantschel, O.; Durnberger, G.; Remsing Rix, L. L.; Planyavsky, M.; Fernbach, N. V.; Kaupe, I.; Bennett, K. L.; Valent, P.; Colinge, J.; Kocher, T.; Superti-Furga, G. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets Blood 2007, 110 (12) 4055-4063
20. Daub, H.; Olsen, J. V.; Bairlein, M.; Gnad, F.; Oppermann, F. S.; Korner, R.; Greff, Z.; Keri, G.; Stemmann, O.; Mann, M. Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle Mol. Cell 2008, 31 (3) 438-448
21. Manning, B. D.; Cantley, L. C. Akt/PKB signaling: navigating downstream Cell 2007, 129 (7) 1261-1274
22. Garcia-Echeverria, C.; Sellers, W. R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer Oncogene 2008, 27 (41) 5511-5526
23. Altomare, D. A.; Testa, J. R. Perturbations of the Akt signaling pathway in human cancer Oncogene 2005, 24 (50) 7455-7464
24. Vivanco, I.; Sawyers, C. L. The phosphatidylinositol 3-kinase Akt pathway in human cancer Nat. Rev. Cancer 2002, 2 (7) 489-501
25. Franke, T. F. PI3K/Akt: getting it right matters Oncogene 2008, 27 (50) 6473-6488
26. Lu, Y.; Wang, H.; Mills, G. B. Targeting PI3K-Akt pathway for cancer therapy Rev Clin Exp Hematol 2003, 7 (2) 205-228
27. Heerding, D. A.; Rhodes, N.; Leber, J. D.; Clark, T. J.; Keenan, R. M.; Lafrance, L. V.; Li, M.; Safonov, I. G.; Takata, D. T.; Venslavsky, J. W.; Yamashita, D. S.; Choudhry, A. E.; Copeland, R. A.; Lai, Z.; Schaber, M. D.; Tummino, P. J.; Strum, S. L.; Wood, E. R.; Duckett, D. R.; Eberwein, D.; Knick, V. B.; Lansing, T. J.; McConnell, R. T.; Zhang, S.; Minthorn, E. A.; Concha, N. O.; Warren, G. L.; Kumar, R. Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3- yl)-1-ethyl-7-{[(3 S)-3-piperidinylmethyl]oxy}-1 H -imidazo[4,5- c ]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of Akt kinase J. Med. Chem. 2008, 51 (18) 5663-5679
28. Pal, S. K.; Reckamp, K.; Yu, H.; Figlin, R. A. Akt inhibitors in clinical development for the treatment of cancer Expert Opin. Invest. Drugs 2010, 19 (11) 1355-1366
29. Blake, J. F.; Xu, R.; Bencsik, J. R.; Xiao, D.; Kallan, N. C.; Schlachter, S.; Mitchell, I. S.; Spencer, K. L.; Banka, A. L.; Wallace, E. M.; Gloor, S. L.; Martinson, M.; Woessner, R. D.; Vigers, G. P.; Brandhuber, B. J.; Liang, J.; Safina, B. S.; Li, J.; Zhang, B.; Chabot, C.; Do, S.; Lee, L.; Oeh, J.; Sampath, D.; Lee, B. B.; Lin, K.; Liederer, B. M.; Skelton, N. J. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors J. Med. Chem. 2012, 55 (18) 8110-8127
30. Kumar, R. IDiscovery of an oral Akt kinase inhibitor. American Association for Cancer Research Annual Meeting, Washington, DC, April 6-10, 2013.
31. Hauck, S. M.; Dietter, J.; Kramer, R. L.; Hofmaier, F.; Zipplies, J. K.; Amann, B.; Feuchtinger, A.; Deeg, C. A.; Ueffing, M. Deciphering membrane-associated molecular processes in target tissue of autoimmune uveitis by label-free quantitative mass spectrometry Mol. Cell. Proteomics 2010, 9 (10) 2292-2305
32. Tai, A. W.; Salloum, S. The role of the phosphatidylinositol 4-kinase PI4KA in hepatitis C virus-induced host membrane rearrangement PLoS One 2011, 6 (10 e26300
33. Levy, D. S.; Kahana, J. A.; Kumar, R. Akt inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines Blood 2009, 113 (8) 1723-1729
34. Rhodes, N.; Heerding, D. A.; Duckett, D. R.; Eberwein, D. J.; Knick, V. B.; Lansing, T. J.; McConnell, R. T.; Gilmer, T. M.; Zhang, S. Y.; Robell, K.; Kahana, J. A.; Geske, R. S.; Kleymenova, E. V.; Choudhry, A. E.; Lai, Z.; Leber, J. D.; Minthorn, E. A.; Strum, S. L.; Wood, E. R.; Huang, P. S.; Copeland, R. A.; Kumar, R. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity Cancer Res. 2008, 68 (7) 2366-2374
35. Altomare, D. A.; Zhang, L.; Deng, J.; Di Cristofano, A.; Klein-Szanto, A. J.; Kumar, R.; Testa, J. R. GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt Clin. Cancer Res. 2010, 16 (2) 486-496
36. Mallick, P.; Kuster, B. Proteomics: a pragmatic perspective Nat. Biotechnol. 2010, 28 (7) 695-709
37. Lemeer, S.; Zorgiebel, C.; Ruprecht, B.; Kohl, K.; Kuster, B. Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity J. Proteome Res. 2013, 12 (4) 1723-1731
38. Carter, C. A.; Kane, C. J. Therapeutic potential of natural compounds that regulate the activity of protein kinase C Curr. Med. Chem. 2004, 11 (21) 2883-2902
39. Hofmann, J. Protein kinase C isozymes as potential targets for anticancer therapy Curr. Cancer Drug Targets 2004, 4 (2) 125-146
40. Teicher, B. A. Protein kinase C as a therapeutic target Clin. Cancer Res. 2006, 12 (18) 5336-5345
41. Riento, K.; Ridley, A. J. Rocks: multifunctional kinases in cell behaviour Nat. Rev. Mol. Cell Biol. 2003, 4 (6) 446-456
42. Dummler, B.; Ohshiro, K.; Kumar, R.; Field, J. Pak protein kinases and their role in cancer Cancer Metastasis Rev. 2009, 28 (1-2) 51-63
43. Heikkila, T.; Wheatley, E.; Crighton, D.; Schroder, E.; Boakes, A.; Kaye, S. J.; Mezna, M.; Pang, L.; Rushbrooke, M.; Turnbull, A.; Olson, M. F. Co-crystal structures of inhibitors with MRCKbeta, a key regulator of tumor cell invasion PLoS One 2011, 6 (9 e24825
44. Piazza, F.; Manni, S.; Semenzato, G. Novel players in multiple myeloma pathogenesis: role of protein kinases CK2 and GSK3 Leuk Res 2013, 37 (2) 221-227
45. Kim, H. M.; Kim, C. S.; Lee, J. H.; Jang, S. J.; Hwang, J. J.; Ro, S.; Choi, J. CG0009, a novel glycogen synthase kinase 3 inhibitor, induces cell death through cyclin D1 depletion in breast cancer cells PLoS One 2013, 8 (4 e60383
46. Crouthamel, M. C.; Kahana, J. A.; Korenchuk, S.; Zhang, S. Y.; Sundaresan, G.; Eberwein, D. J.; Brown, K. K.; Kumar, R. Mechanism and management of Akt inhibitor-induced hyperglycemia Clin. Cancer Res. 2009, 15 (1) 217-225
47. Assie, G. One single signaling pathway for so many different biological functions: lessons from the cyclic adenosine monophosphate/protein kinase A pathway-related diseases J. Clin. Endocrinol. Metab. 2012, 97 (12) 4355-4357
48. Pearce, L. R.; Komander, D.; Alessi, D. R. The nuts and bolts of AGC protein kinases Nat. Rev. Mol. Cell Biol. 2010, 11 (1) 9-22
49. Hofmann, F. The biology of cyclic GMP-dependent protein kinases J. Biol. Chem. 2005, 280 (1) 1-4
50. Lincoln, T. M.; Dey, N.; Sellak, H. Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression J. Appl. Physiol. 2001, 91 (3) 1421-1430
51. Lohmann, S. M.; Vaandrager, A. B.; Smolenski, A.; Walter, U.; De Jonge, H. R. Distinct and specific functions of cGMP-dependent protein kinases Trends Biochem. Sci. 1997, 22 (8) 307-312
52. Orstavik, S.; Natarajan, V.; Tasken, K.; Jahnsen, T.; Sandberg, M. Characterization of the human gene encoding the type I alpha and type I beta cGMP-dependent protein kinase (PRKG1) Genomics 1997, 42 (2) 311-318
53. McAllister, F. E.; Niepel, M.; Haas, W.; Huttlin, E.; Sorger, P. K.; Gygi, S. P. Mass spectrometry based method to increase throughput for kinome analyses using ATP probes Anal. Chem. 2013, 85 (9) 4666-4674
54. Schirle, M.; Bantscheff, M.; Kuster, B. Mass spectrometry-based proteomics in preclinical drug discovery Chem. Biol. 2012, 19 (1) 72-84
55. Zhang, L.; Holmes, I. P.; Hochgrafe, F.; Walker, S. R.; Ali, N. A.; Humphrey, E. S.; Wu, J.; de Silva, M.; Kersten, W. J. A.; Connor, T.; Falk, H.; Allan, L.; Street, I. P.; Bentley, J. D.; Pilling, P. A.; Monahan, B. J.; Peat, T. S.; Daly, R. J. Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling. J. Proteome Res. 2013.